Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study

AIMS: To determine tolerability and the optimal dose regimen of the soluble guanylate cyclase stimulator vericiguat in patients with chronic heart failure and preserved ejection fraction (HFpEF). METHODS AND RESULTS: SOCRATES-PRESERVED was a prospective, randomized, placebo-controlled double-blind,...

Descripción completa

Detalles Bibliográficos
Autores principales: Pieske, Burkert, Maggioni, Aldo P., Lam, Carolyn S.P., Pieske-Kraigher, Elisabeth, Filippatos, Gerasimos, Butler, Javed, Ponikowski, Piotr, Shah, Sanjiv J., Solomon, Scott D., Scalise, Andrea-Viviana, Mueller, Katharina, Roessig, Lothar, Gheorghiade, Mihai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Fast Track Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400074/
https://www.ncbi.nlm.nih.gov/pubmed/28369340
http://dx.doi.org/10.1093/eurheartj/ehw593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400074/
https://www.ncbi.nlm.nih.gov/pubmed/28369340
http://dx.doi.org/10.1093/eurheartj/ehw593

Ejemplares similares